Subject
Radiology Nuclear Medicine and imaging,Oncology,General Medicine
Reference127 articles.
1. Bayer Healthcare Pharmaceuticals Inc. Regorafenib (Stivarga). U.S Food and Drug Administration Prescribing Information; 2019.
2. Bayer AG. Regorafenib (Stivarga). Summary of product characteristics. European Medicines Agency; 2018.
3. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial;Grothey;Lancet,2013
4. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial;Li;Lancet Oncol,2015
5. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial;Demetri;Lancet,2013
Cited by
62 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献